Variations in erythropoiesis and serum ferritin during erythropoietin therapy for anaemia of end-stage renal disease

G. Barosi, C. Merlo, P. Palestra, N. L. Liberato, R. Guarnone, F. Di Dio, V. Piazza, A. Salvadeo

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

In order to study the relationship between erythropoiesis and serum ferritin (SF) during erythropoietin (rHuEPO) therapy in the anaemia of end-stage renal disease (ESRD), 19 patients were followed without iron supplementation and at a fixed dose of the drug (40 U/kg). Twelve patients failed to attain the target haemoglobin (Hb) value, 7 of whom due to the appearance of iron deficiency. Erythropoiesis, as measured by the serum transferrin receptor concentration, increased from 12 to 120% of the basal value. This increment was not constantly associated with a proportional rise of Hb or reticulocyte count. SF decreased exponentially from a median value of 221 μg/dl (range 42-470) to a median value of 54 μg/dl (range 20-172). Halving of the basal SF value (SF-T50) was reached at the 18th-95th day of therapy (median = 43), representing a iron shift of 3.4-11.6 mg/day (median = 5.4). SF-T50 was not correlated with the Hb increase, but with that of erythropoiesis (r = 0.78; p = 0.003). The minimum SF (MSF) value attained was not correlated with the appearance of iron deficiency. The conclusion is that the rate of SF decrease during rHuEPO in ESRD is a reliable measure of iron mobilisation for erythropoiesis, but not for haematologic response. The MSF value reached during therapy is not representative of available iron for erythropoiesis.

Original languageEnglish
Pages (from-to)13-18
Number of pages6
JournalActa Haematologica
Volume90
Issue number1
Publication statusPublished - 1993

Fingerprint

Erythropoiesis
Ferritins
Erythropoietin
Chronic Kidney Failure
Anemia
Iron
Serum
Hemoglobins
Therapeutics
Reticulocyte Count
Transferrin Receptors
Pharmaceutical Preparations

Keywords

  • Anaemia of renal failure
  • Erythropoiesis
  • Erythropoietin
  • Iron deficiency
  • Serum ferritin
  • Serum transferrin receptor

ASJC Scopus subject areas

  • Hematology

Cite this

Variations in erythropoiesis and serum ferritin during erythropoietin therapy for anaemia of end-stage renal disease. / Barosi, G.; Merlo, C.; Palestra, P.; Liberato, N. L.; Guarnone, R.; Di Dio, F.; Piazza, V.; Salvadeo, A.

In: Acta Haematologica, Vol. 90, No. 1, 1993, p. 13-18.

Research output: Contribution to journalArticle

Barosi, G, Merlo, C, Palestra, P, Liberato, NL, Guarnone, R, Di Dio, F, Piazza, V & Salvadeo, A 1993, 'Variations in erythropoiesis and serum ferritin during erythropoietin therapy for anaemia of end-stage renal disease', Acta Haematologica, vol. 90, no. 1, pp. 13-18.
Barosi, G. ; Merlo, C. ; Palestra, P. ; Liberato, N. L. ; Guarnone, R. ; Di Dio, F. ; Piazza, V. ; Salvadeo, A. / Variations in erythropoiesis and serum ferritin during erythropoietin therapy for anaemia of end-stage renal disease. In: Acta Haematologica. 1993 ; Vol. 90, No. 1. pp. 13-18.
@article{42bb8a73270949ca9738223cf7ba14e6,
title = "Variations in erythropoiesis and serum ferritin during erythropoietin therapy for anaemia of end-stage renal disease",
abstract = "In order to study the relationship between erythropoiesis and serum ferritin (SF) during erythropoietin (rHuEPO) therapy in the anaemia of end-stage renal disease (ESRD), 19 patients were followed without iron supplementation and at a fixed dose of the drug (40 U/kg). Twelve patients failed to attain the target haemoglobin (Hb) value, 7 of whom due to the appearance of iron deficiency. Erythropoiesis, as measured by the serum transferrin receptor concentration, increased from 12 to 120{\%} of the basal value. This increment was not constantly associated with a proportional rise of Hb or reticulocyte count. SF decreased exponentially from a median value of 221 μg/dl (range 42-470) to a median value of 54 μg/dl (range 20-172). Halving of the basal SF value (SF-T50) was reached at the 18th-95th day of therapy (median = 43), representing a iron shift of 3.4-11.6 mg/day (median = 5.4). SF-T50 was not correlated with the Hb increase, but with that of erythropoiesis (r = 0.78; p = 0.003). The minimum SF (MSF) value attained was not correlated with the appearance of iron deficiency. The conclusion is that the rate of SF decrease during rHuEPO in ESRD is a reliable measure of iron mobilisation for erythropoiesis, but not for haematologic response. The MSF value reached during therapy is not representative of available iron for erythropoiesis.",
keywords = "Anaemia of renal failure, Erythropoiesis, Erythropoietin, Iron deficiency, Serum ferritin, Serum transferrin receptor",
author = "G. Barosi and C. Merlo and P. Palestra and Liberato, {N. L.} and R. Guarnone and {Di Dio}, F. and V. Piazza and A. Salvadeo",
year = "1993",
language = "English",
volume = "90",
pages = "13--18",
journal = "Acta Haematologica",
issn = "0001-5792",
publisher = "S. Karger AG",
number = "1",

}

TY - JOUR

T1 - Variations in erythropoiesis and serum ferritin during erythropoietin therapy for anaemia of end-stage renal disease

AU - Barosi, G.

AU - Merlo, C.

AU - Palestra, P.

AU - Liberato, N. L.

AU - Guarnone, R.

AU - Di Dio, F.

AU - Piazza, V.

AU - Salvadeo, A.

PY - 1993

Y1 - 1993

N2 - In order to study the relationship between erythropoiesis and serum ferritin (SF) during erythropoietin (rHuEPO) therapy in the anaemia of end-stage renal disease (ESRD), 19 patients were followed without iron supplementation and at a fixed dose of the drug (40 U/kg). Twelve patients failed to attain the target haemoglobin (Hb) value, 7 of whom due to the appearance of iron deficiency. Erythropoiesis, as measured by the serum transferrin receptor concentration, increased from 12 to 120% of the basal value. This increment was not constantly associated with a proportional rise of Hb or reticulocyte count. SF decreased exponentially from a median value of 221 μg/dl (range 42-470) to a median value of 54 μg/dl (range 20-172). Halving of the basal SF value (SF-T50) was reached at the 18th-95th day of therapy (median = 43), representing a iron shift of 3.4-11.6 mg/day (median = 5.4). SF-T50 was not correlated with the Hb increase, but with that of erythropoiesis (r = 0.78; p = 0.003). The minimum SF (MSF) value attained was not correlated with the appearance of iron deficiency. The conclusion is that the rate of SF decrease during rHuEPO in ESRD is a reliable measure of iron mobilisation for erythropoiesis, but not for haematologic response. The MSF value reached during therapy is not representative of available iron for erythropoiesis.

AB - In order to study the relationship between erythropoiesis and serum ferritin (SF) during erythropoietin (rHuEPO) therapy in the anaemia of end-stage renal disease (ESRD), 19 patients were followed without iron supplementation and at a fixed dose of the drug (40 U/kg). Twelve patients failed to attain the target haemoglobin (Hb) value, 7 of whom due to the appearance of iron deficiency. Erythropoiesis, as measured by the serum transferrin receptor concentration, increased from 12 to 120% of the basal value. This increment was not constantly associated with a proportional rise of Hb or reticulocyte count. SF decreased exponentially from a median value of 221 μg/dl (range 42-470) to a median value of 54 μg/dl (range 20-172). Halving of the basal SF value (SF-T50) was reached at the 18th-95th day of therapy (median = 43), representing a iron shift of 3.4-11.6 mg/day (median = 5.4). SF-T50 was not correlated with the Hb increase, but with that of erythropoiesis (r = 0.78; p = 0.003). The minimum SF (MSF) value attained was not correlated with the appearance of iron deficiency. The conclusion is that the rate of SF decrease during rHuEPO in ESRD is a reliable measure of iron mobilisation for erythropoiesis, but not for haematologic response. The MSF value reached during therapy is not representative of available iron for erythropoiesis.

KW - Anaemia of renal failure

KW - Erythropoiesis

KW - Erythropoietin

KW - Iron deficiency

KW - Serum ferritin

KW - Serum transferrin receptor

UR - http://www.scopus.com/inward/record.url?scp=0027372905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027372905&partnerID=8YFLogxK

M3 - Article

C2 - 8237268

AN - SCOPUS:0027372905

VL - 90

SP - 13

EP - 18

JO - Acta Haematologica

JF - Acta Haematologica

SN - 0001-5792

IS - 1

ER -